The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation. Amoroso C. et al. 2020. Cells, 9, 1234.
Humans host within their guts trillions of microorganisms, including species of bacteria, fungi and other microbes. This microbiome plays a role in many beneficial processes such as the production of essential nutrients, but disbalances in the microbial composition are linked to disease conditions. Several studies have shown that alterations of the gut microbiome may lead to the onset of inflammatory bowel disease (IBD). Consequently, therapies targeting microbes are being considered to support current treatments for this condition.
In this review, the authors delve into the understanding of host-microbe interactions in IBD and the basis for promoting homeostatic immune responses through microbe-targeted therapies. Advances in this field may lead to the customisation of IBD treatments according to the microbiome status of individual patients, thus managing this condition in a more effective and personalised manner.